[
    [
        {
            "time": "",
            "original_text": "沃森生物股价两连阴 中泰证券资管持股",
            "features": {
                "keywords": [
                    "沃森生物",
                    "股价",
                    "两连阴",
                    "中泰证券资管",
                    "持股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物股价两连阴 中泰证券资管持股",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康希诺、沃森生物大幅调整，疫苗板块连续下滑",
            "features": {
                "keywords": [
                    "康希诺",
                    "沃森生物",
                    "大幅调整",
                    "疫苗板块",
                    "连续下滑"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康希诺、沃森生物大幅调整，疫苗板块连续下滑",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【东北医药刘宇腾】沃森生物（300142）的动态点评：Omicron持续发酵，弯道超车机遇凸显",
            "features": {
                "keywords": [
                    "东北医药",
                    "刘宇腾",
                    "沃森生物",
                    "Omicron",
                    "持续发酵",
                    "弯道超车",
                    "机遇"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【东北医药刘宇腾】沃森生物（300142）的动态点评：Omicron持续发酵，弯道超车机遇凸显",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]